Prasugrel - Investigational Antiplatelet Agent

The results of the phase III trial of Prasugrel

The results of the phase III trial showed that treatment with prasugrel was associated with a significant reduction in the composite primary efficacy endpoint as well as in MI, urgent target vessel revascularisation (TVR), and stent thrombosis.


«Back	\|	Next»

| 1 | 2 | 3 | 4 | 5 |

Browse More Images - Return to Project